Centinel Spine® Completes Enrollment in First-of-its-Kind 2-Level IDE Trial Evaluating prodisc® C Match-the-Disc™ Cervical TDR System

• The trial is designed to evaluate the safety and effectiveness of the prodisc C Vivo and prodisc C SK system by comparing it with an approved total disc replacement (TDR) product as a control for 2-level indications.
• The trial gives surgeons the unique opportunity to choose the disc that best fits the patient's anatomy.
• The 2-level prodisc C Vivo and prodisc C SK trial enrolled 431 Subjects at 29 sites across the United States.

WEST CHESTER, Pa., June 13, 2023 /PRNewswire/ -- Centinel Spine^®, LLC, ("the Company") a leading global medical device company addressing cervical and lumbar spinal disease by providing the most robust and clinically-proven total disc replacement technology platform in the world (prodisc^®), today announced the completion of enrollment in a first-of-its-kind Investigational Device Exemption (IDE) study evaluating the Company's prodisc C Vivo and prodisc C SK cervical Total Disc Replacement (TDR) system. This is the first IDE trial allowing surgeons to select from two different TDR control devices to treat each surgical level individually.

The prospective, randomized clinical trial is designed to evaluate the safety and effectiveness of the prodisc C Vivo and prodisc C SK system by comparing it with an approved TDR product as a control for 2-level indications, making it the first and only of its kind with two investigational devices and a TDR control. The study includes 431 Subjects at 29 sites throughout the U.S. and with oversight from the U.S. Food and Drug Administration. The study permits surgeons to select the investigational device—the prodisc C Vivo and/or prodisc C SK—based on the patient's anatomy, as well as other surgical factors. The ability to treat each level of two-level disease individually provides surgeons with both increased options and opportunities to match the disc to each patient's anatomical needs.

Orthopedic spine surgeon Jason Tinley, MD, founder of the DFW Center for Spinal Disorders in Dallas-Fort Worth, Texas, commented, "Each of my patients is unique in their cervical spine operative symptoms and anatomy. This IDE study was the first ever to evaluate the safety and efficacy of multiple total disc replacement devices that empower surgeons to tailor their surgical solution to the patient's needs. I've found that prodisc C Vivo and prodisc C SK provide a powerful means to customize my surgical treatment to each patient."

The prodisc C Vivo system has been in clinical use internationally since 2009 and is currently one of the most frequently implanted TDR devices in the world. The device has keel-less fixation and combines a unique anatomically-designed superior endplate with lateral spikes to optimize fit and provide immediate fixation. The prodisc C SK device features a flat endplate designed for optimized implant positioning that allows surgeons to address individual patient anatomy—with a low-profile central keel that provides immediate fixation and enables a streamlined keel preparation technique.

According to Pierce Nunley, orthopedic spine surgeon at Specialists Hospital of Shreveport, Shreveport, Louisiana, "In 25 years of research this was the only FDA study I have ever been in where I got to choose intraoperatively between two different study devices. This is a unique aspect of this study and we are learning that 'one size doesn't fit all' and where it is more appropriate to use different designs of a device. This study will help advance and improve cervical disc replacement surgery for the benefit of our patients."

"This is the first study ever to compare two different spinal devices to an approved TDR product, making it a unique opportunity to extend Centinel Spine's Match-the-Disc™ cervical total disc replacement system to the treatment of two-level disease," said Centinel Spine CEO Steve Murray. "The continued adoption of this cervical total disc replacement technology at one-level propelled Centinel Spine to record revenues and a top market position in the first quarter of 2023. We look forward to further expanding the body of clinical evidence supporting this system and to enabling more surgeons to treat each patient's unique needs."

More information about the clinical trial can be found at www.clinicaltrials.gov using the identifier NCT04012996.

About Centinel Spine, LLC

Centinel Spine^®, LLC is a leading global medical device company addressing cervical and lumbar spinal disease through anterior surgical access. The Company offers a continuum of trusted, brand-name solutions backed by over 30 years of clinical success—providing the most robust and clinically-proven technology platforms in the world.

Centinel Spine continues to advance its pioneering culture and corporate mission to become a catalyst of change in the spine industry and alter the way spine surgery is perceived. Centinel Spine's prodisc platform remains the only technology with multiple motion-preserving solutions for both cervical and lumbar anterior column reconstruction.

For more information, please visit the company's website at www.CentinelSpine.com or contact:

Centinel Spine

Varun Gandhi
Chief Financial Officer
900 Airport Road, Suite 3B
West Chester, PA 19380
Phone: 484-887-8871
Email: [email protected]

SOURCE Centinel Spine, LLC